MetaCap

Prestige Consumer Healthcare (PBH) vs Perrigo (PRGO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Perrigo (PRGO) has outperformed Prestige Consumer Healthcare (PBH) over the past year, gaining 26.1% versus a loss of 16.5%. Over five years, PBH leads with a -12.0% price change compared with -57.8% for PRGO. Prestige Consumer Healthcare is the larger company by market cap ($2.35 billion vs $2.21 billion), about 1.1 times the size, while Perrigo is growing revenue faster (-2.8% vs -4.3%).

On valuation, Perrigo trades at a lower forward P/E (6.9x vs 9.8x for Prestige Consumer Healthcare). Perrigo pays a dividend yielding 7.28%, while Prestige Consumer Healthcare does not currently pay one. Prestige Consumer Healthcare converts more of its revenue into profit, with a net margin of 17.5% versus -33.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PBH-16.48%PRGO+26.11%
+37%+3%-31%
Nov 21, 20251 yearNov 20, 2026
PBH-14.81%PRGO-61.25%
+59%-12%-84%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PBH versus PRGO key metrics
MetricPBHPRGO
Share price$49.63$15.94
Market cap$2.35B$2.21B
1-day change+0.06%-0.62%
YTD return-19.55%+14.51%
1-year return-16.48%+26.11%
5-year return-12.02%-57.81%
P/E ratio (TTM)15.32—
Forward P/E9.766.94
EPS (TTM)$3.24$-12.47
Dividend yield0.00%7.28%
Annual dividend$0.00$1.16
Revenue (latest FY)$1.09B$4.25B
Revenue growth (YoY)-4.31%-2.75%
Net income (latest FY)$190.30M$-1.43B
Gross margin54.71%35.14%
Operating margin28.42%-26.39%
Net margin17.48%-33.51%
52-week high$71.07$17.07
52-week low$41.77$9.23
Distance from 52-week high-30.17%-6.62%
Analyst consensusbuybuy
Avg. price target upside+33.39%+12.92%
Average volume583.25K2.54M
Shares outstanding47.40M138.80M
Employees8908,100
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PRGO has outperformed PBH by 42.6 percentage points over the past year.
  • Perrigo offers a meaningfully higher dividend yield (7.28% vs 0.00%).
  • Prestige Consumer Healthcare is more profitable, keeping 17.5 cents of every revenue dollar as net income versus -33.5 cents for Perrigo.

About Prestige Consumer Healthcare

PBH stock →

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare.

Health Care · Biotechnology: Pharmaceutical Preparations · 890 employees

About Perrigo

PRGO stock →

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments.

Health Care · Biotechnology: Pharmaceutical Preparations · 8,100 employees

PBH vs PRGO FAQ

Which is bigger, Prestige Consumer Healthcare or Perrigo?

Prestige Consumer Healthcare (PBH) is larger, with a market capitalization of $2.35B compared with $2.21B for Perrigo (PRGO).

Which stock has performed better over the past year, PBH or PRGO?

PRGO returned +26.11% over the past 12 months, compared with -16.48% for PBH (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Prestige Consumer Healthcare or Perrigo?

Perrigo pays a dividend yielding 7.28%, while Prestige Consumer Healthcare does not currently pay a regular dividend.

Are Prestige Consumer Healthcare and Perrigo in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons